Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement

References

• Bindu M, Kusum B, Chatanya K, Naga M, Harsha VS, Banji D. 2011. Dissolution enhancement of efavirenz by solid dispersion and PEGylation techniques. Int J Pharm Investig. 1:29–34.
   PubMedGoogle Scholar
• Costa MA, Seiceira RC, Rodrigues CR, Hoffmeister CR, Cabral LM, Rocha HV. 2013. Efavirenz Dissolution Enhancement I: Co-Micronization. Pharmaceutics. 5:1–22.
   Google Scholar
• Dahan A, Miller JM. 2012. The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs. AAPS J. 14:244–51.
   PubMed Web of Science ®Google Scholar
• Detroja C, Chavhan S, Sawant K. 2011. Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study. Sci Pharm. 79: 635–651.
   PubMedGoogle Scholar
• Eerdenbrugh BV, Stuyven B, Froyen L, Humbeeck JV, Martens JA, Augustijns P,, Mooter GV. 2009. Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical Characterization. AAPS Pharm Sci Tech. 10: 44–53.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M. 2008. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res. 10:845–862.
   Web of Science ®Google Scholar
• Deepali G, Elvis M. 2010. UV Spectrophotometric Method for Assay of the Anti-Retroviral Agent Lamivudine in Active Pharmaceutical Ingredient and in its Tablet Formulation. J Young Pharm. 2:417–419.
   PubMedGoogle Scholar
• Kallings LO. 2008. The first postmodern pandemic: 25 years of HIV/AIDS. J Intern Med. 263:218–243.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 59:631–644.
   PubMed Web of Science ®Google Scholar
• Muthu MS, Singh S. 2009. Poly (D, L-Lactide) Nanosuspensions of Risperidone for Parenteral Delivery: Formulation and In-Vitro Evaluation. Curr Drug Deliv. 6:62–68.
   PubMedGoogle Scholar
• Patel GV, Patel VB, Pathak A, Rajput SJ. 2013. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Drug Deliv Ind Pharm. 40:80–91.
   PubMed Web of Science ®Google Scholar
• Patel VR, Agarwal YK. 2011. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2:81–87.
   PubMedGoogle Scholar
• Pathak P, Meziani MJ, Desai T, Sun YP. 2006. Formation and stabilization of ibuprofen nanoparticles in supercritical fluid processing. J Supercrit Fluids. 37:279–286.
   Web of Science ®Google Scholar
• Peltonen L, Hirvonen J. 2010. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 62:1569–1579.
   PubMed Web of Science ®Google Scholar
• Prasanna L, Giddam AK. 2010. Nano-Suspension technology: a review. Int J Pharm Pharm Sci. 2:35–40.
   Google Scholar
• Reverchon E. 1999. Supercritical antisolvent precipitation of micro- and nano-particles. J Supercrit Fluids. 15:1–21.
   Web of Science ®Google Scholar
• Shafer RW, Vuitton DA. 1999. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother. 532: 73–86.
   Web of Science ®Google Scholar
• Van Eerdenbrugh B, Stuyven B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. 2009. Downscaling drug nanosuspension production: processing aspects and physicochemical characterization. AAPS Pharm Sci Tech. 10: 44–53.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Van den Mooter G, Augustijns P. 2008. Top down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 364:64–75.
   PubMed Web of Science ®Google Scholar
• Xia D, Quaa P, Piao H, Suna S, Yinc Y, Cui F. 2010. Preparation of stable nitrendipine nanosuspension using the precipitation– ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 40:325–334.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Matsumoto T, Kuwata K. 2012. Proper calibration of ultrasonic power enabled the quantitative analysis of the ultrasonication-induced formation process. Protein Sci. 21: 38–49.
   PubMed Web of Science ®Google Scholar
• Zhang Y and Zhang J. 2014. Preparation of budesonide nanosuspensions for pulmonary delivery: Characterization, in vitro release and in vivo lung distribution studies. Artif Cells Nanomed Biotechnol. 6:1–5.
   Google Scholar
• Zhao H, Wang JX, Wang QA, Chen JF, Yun J. 2007. Controlled liquid antisolvent precipitation of hydrophobic pharmaceutical nanoparticles in a microchannel reactor. Ind Eng Chem Res. 46:8229–8235.
   Web of Science ®Google Scholar